Relx PLC (REL)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 2,939.00 |
|---|---|
| 52-week range | 1,991.00 – 3,539.00 |
| Return, 1 month / 3 months | +16.3% / +10.4% |
| Return, 1 year / 3 years | −14.0% / +10.8% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 36.2% |
| Worst drawdown (1 year) | -41.1% |
| Average daily value traded | 11,267.41M GBX |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Relx is an information and analytics company based in the United Kingdom. It provides scientific, technical and medical information and research tools to academic and healthcare customers through its Elsevier business. Its LexisNexis operations supply legal, regulatory and risk data to law firms, insurers and corporations. Relx also runs exhibitions and provides business information and analytics services to professional and commercial customers around the world.
On this site Relx PLC appears as a stock on the London Stock Exchange (UK), code REL, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Relx PLC (REL) trades on the London Stock Exchange in UK. It last closed at GBX 2,939.00 on 27 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,365 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 14.0% and over the last three months it rose 10.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 16.5% | ||
| From 52-week high | -16.3% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 10.4% | ||
| 6-month return | 11.3% | ||
| 12-month return, skipping the last month | -26.1% | ||
| Stability (higher is calmer) | 39 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.1% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 11,267.41M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | +16.3% |
| 3 months | +10.4% |
| 6 months | +11.3% |
| 1 year | −14.0% |
| 3 years | +10.8% |
| 5 years | +44.5% |
Signals
| 50-day / 200-day average | 2,646.84 / 2,521.99 |
|---|---|
| Golden / death cross (60 days) | Golden, 29 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 75.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.2090 |
| 7 May 2026 | GBP 0.4800 |
| 7 Aug 2025 | GBP 0.1950 |
| 8 May 2025 | GBP 0.4480 |
| 1 Aug 2024 | GBP 0.1820 |
| 2 May 2024 | GBP 0.4180 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.